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Edited by Veli-Pekka LehtoAbstract AMP-activated protein kinase (AMPK) plays a crit-
ical role in maintaining energy homeostasis and cardiac function
during ischemia in the heart. However, the functional role of
AMPK in the heart during exercise is unknown. We examined
whether acute exercise increases AMPK activity in mouse hearts
and determined the signiﬁcance of these increases by studying
transgenic (TG) mice expressing a cardiac-speciﬁc dominant-
negative (inactivating) AMPKa2 subunit. Exercise increased
cardiac AMPKa2 activity in the wild type mice but not in TG.
We found that inactivation of AMPK did not result in abnormal
ATP and glycogen consumption during exercise, cardiac func-
tion assessed by heart rhythm telemetry and stress echocardiog-
raphy, or in maximal exercise capacity.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Adequate cardiac function during exercise depends on the
capacity of the heart to sustain cellular ATP during this time
of high energy consumption. The AMP-activated protein ki-
nase (AMPK) is an enzyme that acts as a ‘‘fuel gauge’’, being
activated during conditions associated with energy depletion
[1,2] such as muscle contraction in the skeletal muscle [3] and
by ischemia in the heart [4–6]. The AMPK is a heterotrimeric
protein, consisting of an a subunit which has the catalytic do-
main, and the b and c regulatory subunits [1,2]. There are two
isoforms of the a subunit, two b subunit isoforms and three c
subunits isoforms. The a1 subunit isoform is widely distrib-
uted, while the a2 isoform is expressed mainly in the heart,
skeletal muscle and liver [7].
AMPK is activated by increases in the AMP/ATP and cre-
atine/phosphocreatine ratios through mechanisms which in-*Corresponding author. Fax: +1 617 732 2650.
E-mail address: Laurie.goodyear@joslin.harvard.edu (L.J. Goodyear).
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doi:10.1016/j.febslet.2005.02.052volve allosteric modiﬁcation and phosphorylation by one or
more upstream AMPK kinases [1,2]. Upon activation,
AMPK modiﬁes several metabolic and cellular pathways,
such as increasing cellular glucose transport and fatty acid
oxidation with the goal to restore energy homeostasis. It
has been shown that treadmill exercise in rats causes an in-
crease in AMPK phosphorylation and activity in the heart,
suggesting that AMPK may be important to sustain adequate
cardiac function during exercise [8]. In the present study, we
assessed the consequences of acute exercise on AMPK activ-
ity in mouse hearts and determined the physiologic signiﬁ-
cance of the changes in AMPK activity by studying the
cardiac function during acute exercise in transgenic (TG)
mice with cardiac-speciﬁc overexpression of a dominant-
negative a2 subunit.2. Methods
2.1. Experimental animals
The generation of the TG mice overexpressing dominant-negative
AMPKa2 subunit has been described previously [5]. Brieﬂy, a full-
length cDNA of rat AMPK a2 subunit was tagged at the 5 0 end with
a HA epitope, and a D157A mutation was done to inhibit its catalytic
activity [9,10]. Cardiac-speciﬁc expression of the transgene was con-
ferred with a mouse a-myosin heavy chain promoter. The TG mice
were generated by injecting the recombinant DNA construct into fer-
tilized FVB mouse oocytes, founders were identiﬁed by the polymerase
chain reaction method, and transgene expression was conﬁrmed by
Western blotting of the HA tag. Three TG lines were established
and mice from F2 and F3 generations were used for this study. Ani-
mals were housed in an animal room maintained at 23 C with a
12 h light/12 h dark cycle and fed standard laboratory chow and water
ad libitum. The acute exercise studies were done at 12 PM after re-
moval of food at 7 AM. The animals were allowed to eat during the
previous 12 h dark cycle (from 7 PM to 7 AM). All the procedures
were approved by the Institutional Animal Care and Use Committee
of the Joslin Diabetes Center.
2.2. Treadmill exercise studies
We ﬁrst examined the eﬀect of acute exercise on AMPK activity in
the heart. The mice were previously accustomed to a treadmill (Quin-
ton model 42) by exercising them for two days at 5.4 m/min for 5 min.
We used the same protocol as the one implemented by Coven et al. [8]
in rats, with the exception that we exercised the mice for 30 min instead
of 10 min. In our preliminary studies, 10 min was not suﬃcient to acti-
vate AMPK. Thus, 8–12 week old mice exercised on the treadmill forblished by Elsevier B.V. All rights reserved.
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Fig. 1. Eﬀect of acute exercise on AMPK activity. AMPKa1 and a2
activities were measured in hearts from male WT and TG mice at rest
(sed) or after treadmill exercise (ex) for 30 min at 27 m/min and 15
incline as described in Section 2. Data in means ± S.E., n = 4–6 per
group, P < 0.05.
2046 N. Musi et al. / FEBS Letters 579 (2005) 2045–205030 min at 27 m/min at a 15 incline. After exercise, the mice were sac-
riﬁced by cervical dislocation and the hearts were rapidly removed and
snap-frozen in liquid nitrogen.
Maximal exercise tolerance was determined in 8–12 week old mice
that were subjected to a ‘‘ramp’’ treadmill running protocol, modiﬁed
from that previously described [11]. No diﬀerences in exercise tolerance
were noted between the 8- and 12-week-old mice. Mice exercised at
5.4 m/min, 0 incline for 3 min; 10.8 m/min, 2 for 3 min; 16.1 m/
min, 4 for 3 min; and 22 m/min, 6 for 3 min. Subsequently, at a con-
stant speed of 22 m/min, the incline was increased 2 every 3 min until
14 incline was achieved at min 21 (from test initiation). This speed and
incline were maintained for an additional 30 min at which time the in-
cline was increased 2 every 3 min until a 22 m/min treadmill speed and
a 26 incline was achieved. This speed and incline were maintained un-
til the last mouse stopped running from exhaustion. Maximal exercise
tolerance was determined by the cumulative amount of work (kJ) that
the mice performed, calculated as body weight (kg) · vertical distance
covered (m) · 9.81.
2.3. AMPK activity assay and Western blotting
Freeze-clamped heart muscles were homogenized as previously de-
scribed and lysates were used for AMPK activity assays and for Wes-
tern blotting [12]. In brief, AMPK activity was determined after
immunoprecipitating 200 lg protein using antibodies made against
the amino acid sequences 339–358 of rat AMPKa1 and 352–366 of
a2 [12]. The kinase reaction was done using 200 lM SAMS peptide
as substrate. AMPK activity is expressed as incorporated ATP pico-
moles per mg protein per minute. For Western blotting analysis, pro-
teins (40 lg) from the heart lysates were separated by 8% SDS–PAGE
and transferred to nitrocellulose membranes. After blocking the mem-
branes with 2.5% BSA/TBST, they were probed overnight at 4 C with
antibodies against anti-phospho-acetyl CoA carboxylase (ACC) (rec-
ognizes Ser79 of ACC-1 and the analogous Ser218 of ACC-2) (1:1000,
Upstate, Waltham, MA), anti-phospho-Thr180/Tyr181 p38 mitogen-
activated protein kinase (p38 MAPK) (1:1000, Cell Signaling), or
anti-phospho-Ser189/207 MAPK kinase 3/6 (pMKK3/6) (1:1000, Cell
Signaling). ACC was detected using streptavidin-HRP conjugate
(2 lg/ml, Pierce, Rockford, IL) and p38 protein by using anti-pan-
p38 antibody (1:1000, Cell Signaling). Bound antibodies were detected
using anti-rabbit immunoglobulin-horseradish peroxidase-linked anti-
body and ECL reagents (Perkin–Elmer, Boston, MA). The bands were
quantiﬁed using ImageQuant software (Molecular Dynamics, Inc).
2.4. Glycogen and ATP concentrations in the heart
For glycogen measurements, heart muscle was hydrolyzed in 2 N
HCl at 100 C for 2.5 h and then neutralized with 2 N NaOH. Glucose
was measured by the hexokinase method using the glucose HK reagent
(Sigma, St. Louis, MO). ATP concentrations were determined in per-
chloric acid extracts of frozen heart muscle according to the method of
Lowry and Passonneau [13].
2.5. Heart rhythm telemetry during exercise
To determine the heart rhythm during exercise, previously accus-
tomed mice were implanted with a telemetry device and underwent
an exercise tolerance test [14]. After implantation of the device, the
animals were allowed to recover for a minimum of three days before
the exercise tolerance test. Continuous ECG recordings were per-
formed as described previously [15]. Mice started running in a tread-
mill at a speed of 10 m/min and the workload was increased every
3 min by 2.5 m/min. The incline was maintained constant at 15
throughout the protocol. The mice achieved a maximal eﬀort within
9–12 min.
2.6. Stress echocardiography
Echocardiography at peak eﬀort was performed using a SONOS-
4500 Hewlett–Packard echocardiograph as described previously [16].
The exercise protocol was similar to the one used for the heart rhythm
telemetry studies.
2.7. Statistical analysis
Data are expressed as means ± S.E. Comparison of means was done
by two-way ANOVA followed by post hoc comparison using the Fish-
ers method.3. Results
3.1. Isoform-speciﬁc AMPK activity
Basal AMPKa1 activity was not signiﬁcantly diﬀerent be-
tween groups (P = 0.15) (Fig. 1A), as previously reported
[5]. There was a modest increase in AMPKa1 activity in wild
type (WT) after exercise. Although this increase did not reach
statistical signiﬁcance when compared to WT hearts at rest
(P = 0.078), it rendered AMPKa1 activity after exercise 2-
fold higher in the WT than in the TG hearts (P < 0.05). Thus,
the overexpression of the dominant-negative AMPKa2
mutant likely had a partial inhibitory eﬀect on AMPKa1
activity.
Basal AMPKa2 activity in the TG mouse hearts was de-
creased to 23% of WT (P < 0.05) (Fig. 1B). Treadmill exercise
caused a 2-fold increase in AMPKa2 activity in hearts from
WT mice (P < 0.05). In the TG mice, exercise tended to in-
crease AMPKa2 activity by 1.7-fold compared with baseline,
however, this trend did not reach statistical signiﬁcance
(P = 0.06). Importantly, in the TG mice exercise-stimulated
AMPKa2 activity was only 38% of basal activity of the WT
mice. Moreover, exercise-stimulated AMPKa2 activity was
5.6-fold higher in the WT compared with the TG hearts
(P < 0.05). These ﬁndings show that overexpression of domi-
nant-negative a2 subunit signiﬁcantly blocked the increase in
AMPK activity caused by exercise.
Table 1
Glycogen and ATP content in the heart
Glycogen (nmol/mg) ATP (nmol/mg)
WT TG WT TG
Basal 10 ± 0.9 9.3 ± 0.9 5 ± 0.4 4.7 ± 0.2
Postexercise 7.6 ± 0.5* 7.2 ± 0.5* 3.7 ± 0.5* 3.3 ± 0.4*
Data are means ± S.E.M. n = 4–6 per group.
*P < 0.05 basal vs. postexercise within same group.
Fig. 3. Eﬀect of exercise on p38 and MKK3/6 phosphorylation. p38
Thr180/Tyr181 (A) and MKK3/6 Ser189/207 (B) phosphorylation in the
heart were measured at rest (sed) and after treadmill exercise (ex) for
30 min at 27 m/min and 15 incline as described in Section 2. Graphical
data are means ± S.E., n = 4–6 per group, P < 0.05. Representative
blots are also shown for two hearts in each group.
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Basal glycogen concentrations were similar in the WT and
TG hearts (Table 1) and exercise caused a 24% and a 23%
reduction in the glycogen concentrations in the WT and TG
groups, respectively (P < 0.05 vs. basal in both groups). There
were no diﬀerences in basal ATP concentrations between
groups, and exercise caused a 27% and a 29% decrease in car-
diac ATP concentrations in WT and TG mice, respectively
(P < 0.05 vs. basal in both groups) (Table 1). There were no
signiﬁcant diﬀerences in the magnitude of the exercise-induced
decreases in cardiac glycogen and ATP concentrations between
WT and TG mice.
3.3. ACC and p38 phosphorylation
ACC is phosphorylated and inactivated by AMPK and inac-
tivation of ACC plays an important role in the stimulation of
fatty acid oxidation in the skeletal muscle and liver. There was
only a minor trend for an increase in ACC Ser79/218 phosphor-
ylation after exercise in the WT hearts (Fig. 2). Yet, this ten-
dency was not observed in the TG, leading to a small but
signiﬁcant decrease in ACC phosphorylation after exercise
compared with the WT mice (P < 0.05). ACC protein was
not changed in the TG mice.
Acute exercise strongly increased p38 phosphorylation in the
WT hearts (P < 0.05) (Fig. 3A). In the TG hearts basal p38
phosphorylation was elevated more than 2-fold compared with
the WT and p38 phosphorylation did not increase further with
exercise. Because activation of p38 occurs via dual phosphor-
ylation of conserved motifs by the MAPK kinases, MKK3
and MKK6 [17], we examined the eﬀect of acute exercise onFig. 2. Eﬀect of exercise on ACC phosphorylation. ACC Ser79/218
phosphorylation in the heart was measured at rest (sed) and after
treadmill exercise (ex) for 30 min at 27 m/min and 15 incline as
described in Section 2. Graphical data are means ± S.E., n = 4–6 per
group, P < 0.05. Representative blots are also shown for two hearts in
each group.MKK3/6 phosphorylation. Similar to p38, acute exercise sig-
niﬁcantly increased MKK3/6 phosphorylation in the WT mice
(Fig. 3B). Yet, in contrast to p38, we did not observe an in-
crease in basal MKK3/6 phosphorylation in the TG mice. Fur-
thermore, unlike p38, exercise did increase MKK3/6
phosphorylation in the TG mice.
3.4. Heart rhythm telemetry and stress echocardiography
To characterize the functional role of AMPK in the heart
during exercise, heart rhythm telemetry and echocardiography
were performed. During telemetry, the mean heart rate during
peak exercise was 786 ± 16 beats per minute (bpm) in the WT
mice and 780 ± 11 bpm in the TG (non-signiﬁcant diﬀerence,
n = 4 per group). There were no arrhythmias in the TG group
during exercise, and these mice had normal PR intervals and
QRS complexes. Thus inactivation of AMPKa2 does not lead
to pre-excitation, opposite to what occurs with the hearts car-
rying mutations in the c2 AMPK subunit, which are associated
with pre-excitation [18–20]. Stress echocardiography was also
performed to assess cardiac function at peak eﬀort. The ven-
tricular contractile function at peak eﬀort was similar between
the WT and TG mice (mean fractional shortening was 75 ± 2%
in WT and 72 ± 3% in TG mice, n = 5 per group), despite the
inability of the TG hearts to increase AMPKa2 activity during
exercise.
3.5. Maximal exercise tolerance
We determined maximal exercise tolerance using a tread-
mill running protocol in which the speed and incline were in-
creased progressively until fatigue, to test whether the lack of
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Fig. 4. Maximal exercise tolerance. WT and TG mice exercised on the
treadmill until fatigue using a ‘‘ramp’’ protocol to determine maximal
exercise tolerance. Data are in means ± S.E. (A) Female (n = 8 per
group). (B) Male mice (n = 5 per group).
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fect on exercise tolerance. Fig. 4 shows that in the TG female
mice there was a trend for decreased maximal exercise capac-
ity, however, this small tendency was not statistically signiﬁ-
cant (P = 0.24) (Fig. 4A). In the males, maximal exercise
tolerance was similar in the WT and TG mice (P = 0.67)
(Fig. 4B).4. Discussion
In the present study, we ﬁrst examined whether exercise in-
creases AMPK activity in mouse hearts. In the hearts from
WT mice acute exercise caused a signiﬁcant increase in AMP-
Ka2 activity. This ﬁnding is consistent with a previous study
done in rats in which AMPKa2 activity in the heart increased
in response to acute exercise and that this isoform was more
sensitive to the eﬀects of exercise compared with AMPKa1
[8]. These results are also consistent with the eﬀects of exercise
on isoform-speciﬁc activity in the skeletal muscle because acute
exercise causes a more potent activation of AMPKa2 than a1
[3]. AMPKa2, rather than a1, seems to be more responsive to
acute exercise in the heart.
AMPK has been implicated in the regulation of glycogen
metabolism. Mutations in the AMPKc2 subunit causes mas-
sive glycogen accumulation in the heart [20] and overexpres-
sion of a kinase-deﬁcient AMPK (K45R) in skeletal muscle
leads to lower skeletal muscle glycogen concentrations [21].
In the current study we found that the signiﬁcant reductionin basal AMPKa2 activity present in the TG hearts did not
cause alterations in cardiac glycogen concentrations. Further-
more, exercise lead to a similar degree of glycogen consump-
tion in the heart from WT and TG mice. AMPK
phosphorylates and activates heart 6-phosphofructo-2-kinase
(PFK-2) in vitro and in intact cells [22]. It has been suggested
that AMPK contributes to enhanced glycolysis during ische-
mia by activating PFK-2, the enzyme responsible for the syn-
thesis of fructose 2,6-bisphosphate, a potent stimulator of
glycolysis [22]. In this study, we found a similar breakdown
of glycogen in TG hearts during exercise, suggesting that
AMPKa2 activity is not required for stimulating glycolysis un-
der our experimental conditions. Because there was some
residual AMPKa2 activity in the TG hearts, it is possible that
it was suﬃcient to activate PFK-2 and in this manner stimulate
glycolysis. Future studies will help to clarify whether AMPK
regulates PFK-2-mediated glycolysis during exercise.
AMPK activity increases with changes in cellular energy
stores and functions to maintain ATP levels. We found that
hearts from the TG mice had normal ATP concentrations in
the basal state and that exercised-induced ATP depletion was
not accelerated in these mice compared with the WT, indicat-
ing that AMPKa2 is not indispensable to sustain ATP in the
heart during exercise. This is in contrast to previous ﬁndings
that AMPK plays a critical role in maintaining myocardial
ATP concentrations during ischemia [5,6]. Collectively, these
results support the notion that the functional role of AMPK
varies under diﬀerent stress conditions. Diﬀerences in the func-
tional role of AMPK, depending on the physiologic stimulus,
have previously been demonstrated in the skeletal muscle,
where AMPK is indispensable for hypoxia- but not contrac-
tion-stimulated glucose transport [23].
In the skeletal muscle the activation of AMPK by exercise
leads to the phosphorylation and deactivation of ACC [24].
This leads to a decrease in malonyl-CoA, relieving its inhibi-
tory eﬀect on carnitine palmitoyltransferase-1 which results
in an increase in mitochondrial ﬂux of fatty acids for their oxi-
dation [24]. In the heart, activation of AMPK by myocardial
ischemia is also associated with decreased ACC activity [4].
We tested whether exercise changed ACC phosphorylation
but found that in hearts from the WT mice there was only a
small trend for an increase in ACC phosphorylation after exer-
cise. Nonetheless, we did not observe this tendency for an in-
crease in ACC phosphorylation in the TG mice, leading to a
signiﬁcant decrease in ACC phosphorylation after exercise
compared with the WT mice. This minimal diﬀerence in
ACC phosphorylation between the WT and TG hearts sug-
gests that the phosphorylation state of ACC is not controlled
solely by AMPK, and that other factors also regulate ACC
phosphorylation and activity.
p38 MAPK is a protein that participates in signaling mech-
anisms controlling cellular responses to cytokines and stress.
In the heart, p38 is involved in the pathogenesis of hypertro-
phy and ischemic injury. Nakamura et al. [25] have demon-
strated that exercise increases p38 phosphorylation in the
mouse heart. It has also been proposed that p38 functions
as a positive downstream mediator of AMPK-regulated glu-
cose transport in skeletal muscle [26] and cardiomyocytes
[27]. Therefore, we predicted that the TG hearts would have
reduced p38 signaling. Consistent with previous ﬁndings [25],
we found that acute exercise strongly increased p38 phos-
phorylation in the WT hearts (Fig. 3A). However, despite a
N. Musi et al. / FEBS Letters 579 (2005) 2045–2050 2049marked reduction in basal AMPKa2 activity in the TG
hearts, basal p38 phosphorylation was higher than the WT
hearts, and p38 phosphorylation did not increase further with
exercise. These ﬁndings do not support a role for p38 as a po-
sitive downstream regulator of AMPK-mediated metabolic
eﬀects in the heart. The reason for the increased p38 phos-
phorylation found in the hearts with inactive AMPK is not
clear. This diﬀerence was not explained by upregulation of
p38 protein content in the TG hearts (Fig. 3A). These ﬁnd-
ings suggest, however, that impaired AMPK function leads
to enhanced cellular stress, even though we did not ﬁnd alter-
ations in cardiac ATP content. It is also possible that there is
cross-talk between the AMPK and p38 signaling pathways
and that p38 activity increases as a compensatory mechanism.
Yet, the TG mice did not have altered MKK3/6 phosphory-
lation, indicating that the dysregulation of p38 in the AMPK
TG mice occurs directly on p38 and not on known upstream
kinases. Upregulation of yet unidentiﬁed signals, other than
MKK3 and MKK6, could also potentially result in increased
p38 phosphorylation.
The TG mice overexpressing a kinase-deﬁcient AMPK in
the skeletal muscle driven by a muscle creatine kinase
(MCK) promoter that were generated by Mu et al. [21] have
decreased exercise tolerance. Because in these mice the ki-
nase-inactive AMPK mutant is expressed in both the skeletal
muscle and the heart it is not clear if the exercise intolerance
is due to either abnormal skeletal muscle or cardiac function.
We found that despite the lack of activation of AMPKa2 in
the heart with exercise, the TG mice displayed normal exer-
cise tolerance during the diﬀerent exercise protocols utilized
during the study. This indicates that the functional capacity
of the skeletal muscle is critical to maintain normal exercise
tolerance. It also suggests that the decreased exercise capacity
in AMPK kinase-deﬁcient mice observed by Mu et al. is
likely due to impaired skeletal muscle function rather than al-
tered cardiac function.
In summary, we found that AMPKa2 activity increases
signiﬁcantly with exercise, yet, blocking the activation of
AMPKa2 in the heart was not associated with decreased exer-
cise tolerance or abnormal cardiac function during peak exer-
cise. It is possible however, that life-long AMPKa2 deﬁciency
may lead to compensation by complementary signaling path-
ways. Also, the residual AMPK activity in the TG mice could
have helped to maintain cardiac function and exercise toler-
ance. Finally, there are AMPK-independent pathways that
are activated during exercise. For example, both calcium-
and protein kinase A-mediated pathways [28] are activated
during exercise and likely play an important role in controlling
the physiologic response to exercise in the heart.
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